Compare RXT & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RXT | VNDA |
|---|---|---|
| Founded | 1998 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.5M | 400.8M |
| IPO Year | 2020 | 2005 |
| Metric | RXT | VNDA |
|---|---|---|
| Price | $1.54 | $6.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $1.71 | ★ $14.90 |
| AVG Volume (30 Days) | ★ 6.3M | 1.0M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.13 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,685,700,000.00 | $216,105,000.00 |
| Revenue This Year | N/A | $21.35 |
| Revenue Next Year | $1.35 | $37.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $0.39 | $3.81 |
| 52 Week High | $2.74 | $9.91 |
| Indicator | RXT | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 56.54 | 43.36 |
| Support Level | $1.34 | $6.57 |
| Resistance Level | $1.57 | $8.29 |
| Average True Range (ATR) | 0.18 | 0.27 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 74.05 | 35.63 |
Rackspace Technology Inc is an end-to-end, hybrid, multi-cloud technology services company. It designs, builds, and operates its customers' cloud environments across all technology platforms, irrespective of technology stack or deployment model. The company's solutions include Application Services, Data, Colocation, Cloud, Managed Hosting, Professional Services, and Security and Compliance. It has two reportable segments: Private Cloud and Public Cloud. Maximum revenue is generated from the Public Cloud segment, which offers cloud solutions through managed services, elastic engineering, and professional services offerings for customer environments hosted on the AWS, Microsoft Azure, and Google Cloud public cloud platforms. Geographically, the company derives its key revenue from the U.S.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.